HLB Life Science Co. Ltd (067630) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HLB Life Science Co. Ltd (067630) has a cash flow conversion efficiency ratio of -0.016x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.30 Billion ≈ $-2.92 Million USD) by net assets (₩277.26 Billion ≈ $187.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HLB Life Science Co. Ltd (067630) balance sheet quality index to measure how much of total assets are equity-financed.
HLB Life Science Co. Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how HLB Life Science Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is HLB Life Science Co. Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
HLB Life Science Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HLB Life Science Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Clene Inc.
NASDAQ:CLNN
|
0.241x |
|
Entera Bio Ltd
NASDAQ:ENTX
|
-0.180x |
|
Deniz Gayrimenkul Yatirim Ortakligi AS
IS:DZGYO
|
0.068x |
|
Jaiprakash Associates Limited
NSE:JPASSOCIAT
|
0.065x |
|
Castellum Inc.
NYSE MKT:CTM
|
0.036x |
|
EuroDry Ltd
NASDAQ:EDRY
|
0.074x |
|
Titanium Oyj
HE:TITAN
|
0.222x |
|
Mandom Indonesia Tbk
JK:TCID
|
0.032x |
Annual Cash Flow Conversion Efficiency for HLB Life Science Co. Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of HLB Life Science Co. Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see HLB Life Science Co. Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩398.83 Billion ≈ $270.28 Million |
₩-32.01 Billion ≈ $-21.69 Million |
-0.080x | -85.25% |
| 2023-12-31 | ₩231.21 Billion ≈ $156.69 Million |
₩-10.02 Billion ≈ $-6.79 Million |
-0.043x | +65.81% |
| 2022-12-31 | ₩234.72 Billion ≈ $159.07 Million |
₩-29.74 Billion ≈ $-20.16 Million |
-0.127x | -121.50% |
| 2021-12-31 | ₩246.19 Billion ≈ $166.84 Million |
₩-14.08 Billion ≈ $-9.54 Million |
-0.057x | -917.36% |
| 2020-12-31 | ₩287.18 Billion ≈ $194.62 Million |
₩2.01 Billion ≈ $1.36 Million |
0.007x | +118.86% |
| 2019-12-31 | ₩333.82 Billion ≈ $226.23 Million |
₩-12.39 Billion ≈ $-8.39 Million |
-0.037x | +26.58% |
| 2018-12-31 | ₩219.09 Billion ≈ $148.47 Million |
₩-11.07 Billion ≈ $-7.50 Million |
-0.051x | -783.95% |
| 2017-12-31 | ₩52.83 Billion ≈ $35.80 Million |
₩-302.04 Million ≈ $-204.69K |
-0.006x | +93.04% |
| 2016-12-31 | ₩27.68 Billion ≈ $18.76 Million |
₩-2.27 Billion ≈ $-1.54 Million |
-0.082x | +51.02% |
| 2015-12-31 | ₩25.90 Billion ≈ $17.55 Million |
₩-4.34 Billion ≈ $-2.94 Million |
-0.168x | -121.60% |
| 2014-12-31 | ₩13.44 Billion ≈ $9.11 Million |
₩10.43 Billion ≈ $7.07 Million |
0.776x | +190.44% |
| 2013-12-31 | ₩11.03 Billion ≈ $7.48 Million |
₩2.95 Billion ≈ $2.00 Million |
0.267x | -86.53% |
| 2012-12-31 | ₩7.04 Billion ≈ $4.77 Million |
₩13.97 Billion ≈ $9.47 Million |
1.984x | -- |
About HLB Life Science Co. Ltd
HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendoc… Read more